\u3ci\u3eRed Hawk Song\u3c/i\u3e / \u3ci\u3eMount Lowe 1978\u3c/i\u3e / \u3ci\u3eHigher\u3c/i\u3e

Red Hawk Song: I admit that I love you. My heart sings strongly through the fires of my body. Mount Lowe 1978: Ruins rambled, too well sifted Higher: Watching the crows\u27 realm, treetop mopers amidst cloud erasers of the blue

The Jost function and Siegert pseudostates from R-matrix calculations at complex wavenumbers

info:eu-repo/semantics/nonPublishe

The Jost function and Siegert pseudostates from R-matrix calculations at complex wavenumbers

The single-channel Jost function is calculatedwith the computational R-matrix on a Lagrange-Jacobi mesh,in order to study its behaviour at complex wavenumbers.Three potentials derived from supersymmetric transforma-tions, two of which never previously studied, are used to testthe accuracy of the method. Each of these potentials, withs-wave or p-wave bound, resonance or virtual states, has asimple analytical expression for the Jost function, which iscompared with the calculated Jost function. Siegert statesand Siegert pseudostates are determined by finding the zerosof the calculated Jost function. Poles of the exact Jost func-tion are not present in the calculated Jost function due to thetruncation of the potential in the R-matrix method. Instead,Siegert pseudostates arise in the vicinity of the missing poles.SCOPUS: ar.jinfo:eu-repo/semantics/publishe

17F breakup reactions: A touchstone for indirect measurements

Dissociation has become an essential tool in several domains of nuclear physics. It provides useful information about the structure of halo nuclei, and Coulomb breakup can be used as an indirect method to measure radiative-capture cross sections at stellar energies. Though simple it may seem, this indirect technique relies on peculiar assumptions. Recent theoretical analyses of the Coulomb breakup of 8B have shown that these assumptions are not all satisfied. Whereas many experimental investigations on such a phenomenon have been conducted on 8B, the case of 17F has been poorly addressed up to now. An exclusive study of 17F breakup reactions has thus been performed at the FRIBs facility of the Laboratori Nazionali del Sud, Catania (Italy). The experimental setup and the detector systems allowed the measurement, event-by-event, of the X-Y coordinates of the interaction point on the target as well as the momenta and angles of all outgoing decay particles with a geometrical efficiency of 72% and a resolution of approximately 300 keV. The first results and preliminary model comparison are reported.info:eu-repo/semantics/publishe

Off-label-dosing of non-vitamin K-dependent oral antagonists in AF patients before and after stroke: results of the prospective multicenter Berlin Atrial Fibrillation Registry

Aims We aimed to analyze prevalence and predictors of NOAC off-label under-dosing in AF patients before and after the index stroke. Methods The post hoc analysis included 1080 patients of the investigator-initiated, multicenter prospective Berlin Atrial Fibrillation Registry, designed to analyze medical stroke prevention in AF patients after acute ischemic stroke. Results At stroke onset, an off-label daily dose was prescribed in 61 (25.5%) of 239 NOAC patients with known AF and CHA2DS2-VASc score ≥ 1, of which 52 (21.8%) patients were under-dosed. Under-dosing was associated with age ≥ 80 years in patients on rivaroxaban [OR 2.90, 95% CI 1.05-7.9, P = 0.04; n = 29] or apixaban [OR 3.24, 95% CI 1.04-10.1, P = 0.04; n = 22]. At hospital discharge after the index stroke, NOAC off-label dose on admission was continued in 30 (49.2%) of 61 patients. Overall, 79 (13.7%) of 708 patients prescribed a NOAC at hospital discharge received an off-label dose, of whom 75 (10.6%) patients were under-dosed. Rivaroxaban under-dosing at discharge was associated with age ≥ 80 years [OR 3.49, 95% CI 1.24-9.84, P = 0.02; n = 19]; apixaban under-dosing with body weight ≤ 60 kg [OR 0.06, 95% CI 0.01-0.47, P < 0.01; n = 56], CHA2DS2-VASc score [OR per point 1.47, 95% CI 1.08-2.00, P = 0.01], and HAS-BLED score [OR per point 1.91, 95% CI 1.28-2.84, P < 0.01]. Conclusion At stroke onset, off-label dosing was present in one out of four, and under-dosing in one out of five NOAC patients. Under-dosing of rivaroxaban or apixaban was related to old age. In-hospital treatment after stroke reduced off-label NOAC dosing, but one out of ten NOAC patients was under-dosed at discharge

Relationship Between Arterial Access and Outcomes in ST-Elevation Myocardial Infarction With a Pharmacoinvasive Versus Primary Percutaneous Coronary Intervention Strategy: Insights From the STrategic Reperfusion Early After Myocardial Infarction (STREAM) Study.

BACKGROUND: The effectiveness of radial access (RA) in ST-elevation myocardial infarction (STEMI) has been predominantly established in primary percutaneous coronary intervention (pPCI) with limited exploration of this issue in the early postfibrinolytic patient. The purpose of this study was to compare the effectiveness and safety of RA versus femoral (FA) access in STEMI undergoing either a pharmacoinvasive (PI) strategy or pPCI. METHODS AND RESULTS: Within STrategic Reperfusion Early After Myocardial Infarction (STREAM), we evaluated the relationship between arterial access site and primary outcome (30-day composite of death, shock, congestive heart failure, or reinfarction) and major bleeding according to the treatment strategy received. A total of 1820 STEMI patients were included: 895 PI (49.2%; rescue PCI [n=379; 42.3%], scheduled PCI [n=516; 57.7%]) and 925 pPCI (50.8%). Irrespective of treatment strategy, there was comparable utilization of either access site (FA: PI 53.4% and pPCI 57.6%). FA STEMI patients were younger, had lower presenting systolic blood pressure, lesser Thrombolysis In Myocardial Infarction risk, and more ∑ST-elevation at baseline. The primary composite endpoint occurred in 8.9% RA versus 15.7% FA patients (P<0.001). On multivariable analysis, this benefit on the primary composite outcome favoring RA persisted (adjusted odds ratio [OR], 0.59; 95% CI, 0.44-0.78; P<0.001) and was evident in both pPCI (adjusted OR, 0.63; 95% CI, 0.43-0.92) and PI cohorts (adjusted OR, 0.57 95% CI, 0.37-0.86; P interaction=0.730). There was no difference in nonintracranial major bleeding with either access group (RA vs FA, 5.2% vs 6.0%; P=0.489). CONCLUSIONS: Regardless of the application of a PI or pPCI strategy, RA was associated with improved clinical outcomes, supporting current STEMI evidence in favor of RA in PCI. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov/. Unique identifier: NCT00623623